7-fluoro-6-methoxy-4-[4-(pyridin-2-ylsulfanyl)-phenylamino]quinoline-3-carbonitrile | 863029-90-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-fluoro-6-methoxy-4-[4-(pyridin-2-ylsulfanyl)-phenylamino]quinoline-3-carbonitrile
• 英文别名: 7-fluoro-6-methoxy-4-(4-pyridin-2-ylsulfanylanilino)quinoline-3-carbonitrile
• CAS: 863029-90-7
• 化学式: C₂₂H₁₅FN₄OS
• 分子量: 402.452
• InChiKey: LUGCXHQFGDVLDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  96.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  7-fluoro-6-methoxy-4-[4-(pyridin-2-ylsulfanyl)-phenylamino]quinoline-3-carbonitrile 、 、 N-甲基吡咯烷酮 在 crude product 、 silica gel 、 methanol-dichloromethane 作用下， 反应 12.0h， 以gives 107 mg of 6-methoxy-4-[4-(pyridin-2-ylsulfanyl)-phenylamino]-7-(4-pyrrolidin-1-yl-piperidin-1-yl)quinoline-3-carbonitrile as a yellow solid, mp 182-184° C.的产率得到6-methoxy-4-[4-(pyridin-2-ylsulfanyl)-phenylamino]-7-(4-pyrrolidin-1-yl-piperidin-1-yl)-quinoline-3-carbonitrile
  参考文献：
  名称：

  3-Quinolinecarbonitrile protein kinase inhibitors

  摘要：

  本发明提供一种公式1的化合物，其中Ar、X、R1、R2、R3和R4如本文所定义，或其药学上可接受的盐，在哺乳动物中预防或抑制与Ras/Raf/MEK信号级联相关的疾病，如肿瘤、中风、骨质疏松症、癌症、类风湿性关节炎、炎症性疾病、多囊肾病和结肠息肉，并提供公式1的化合物及中间体的制备方法。

  公开号：

  US07449460B2
• 作为产物：
  描述：

  4-氯-6-甲氧基7-氟-喹啉-3-甲腈 、 4-(pyridin-2-ylthio)aniline 、 吡啶盐酸盐 以 乙二醇乙醚 为溶剂， 反应 12.0h， 以to provide 830 mg of 7-fluoro-6-methoxy-4-[4-(pyridin-2-ylsulfanyl)-phenylamino]quinoline-3-carbonitrile as an off-white solid, mp 231-233° C.的产率得到7-fluoro-6-methoxy-4-[4-(pyridin-2-ylsulfanyl)-phenylamino]quinoline-3-carbonitrile
  参考文献：
  名称：

  3-Quinolinecarbonitrile protein kinase inhibitors

  摘要：

  本发明提供了一种化合物1的公式，其中Ar，X，R1，R2，R3和R4在此定义，或其药学上可接受的盐，用于预防或抑制哺乳动物中与Ras/Raf/MEK信号级联相关的疾病，如肿瘤、中风、骨质疏松症、癌症、类风湿性关节炎、炎症性疾病、多囊肾病和结肠息肉，并提供制备化合物1和中间体的方法。

  公开号：

  US07767671B2

文献信息

• 3-QUINOLINECARBONITRILE PROTEIN KINASE INHIBITORS
  申请人：Berger Dan Maarten

  公开号：US20090062281A1

  公开（公告）日：2009-03-05

  This invention provides a compound of Formula 1 where Ar, X, R 1 , R 2 , R 3 , and R 4 are defined herein, or a pharmaceutically acceptable salt thereof useful in the prevention or inhibition of diseases associated with the Ras/Raf/MEK signaling cascade in a mammal, such as neoplasms, strokes, osteoporosis, cancer, rheumatoid arthritis, inflammatory disease, polycystic kidney disease, and colonic polyps, and methods of making the compounds of formula 1 and intermediates.

  本发明提供了一种公式1的化合物，其中Ar、X、R1、R2、R3和R4在此定义，或其药学上可接受的盐，用于预防或抑制哺乳动物中与Ras/Raf/MEK信号级联有关的疾病，如肿瘤、中风、骨质疏松症、癌症、类风湿性关节炎、炎症性疾病、多囊肾病和结肠息肉，并提供了制备公式1化合物和中间体的方法。
• Purification of glycosaminoglycan degrading enzymes
  申请人：SEIKAGAKU KOGYO CO., LTD.

  公开号：EP0355831B1

  公开（公告）日：1994-01-26
• SEQUENCE ANALYSIS OF SACCHARIDE MATERIAL
  申请人：CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED

  公开号：EP0788554B1

  公开（公告）日：2000-01-12
• 22438, 23553, 25278, and 26212 novel human sulfatases
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20030162279A1

  公开（公告）日：2003-08-28

  The present invention relates to newly identified human sulfatases. In particular, the invention relates to sulfatase polypeptides and polynucleotides, methods of detecting the sulfatase polypeptides and polynucleotides, and methods of diagnosing and treating sulfatase-related disorders. Also provided are vectors, host cells, and recombinant methods for making and using the novel molecules.
• Novel 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC1A, NARC 25, 86604 and 32222 molecules and uses therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20040009553A1

  公开（公告）日：2004-01-15

  The invention provides isolated nucleic acids molecules and proteins, designated 27411, 23413, 22438, 23553, 25278, 26212, NARC SC1, NARC 10A, NARC 1, NARC 12, NARC 13, NARC 17, NARC 25, NARC 3, NARC 4, NARC 7, NARC 8, NARC 11, NARC 14A, NARC 15, NARC 16, NARC 19, NARC 20, NARC 26, NARC 27, NARC 28, NARC 30, NARC 5, NARC 6, NARC 9, NARC 10C, NARC 8B, NARC 9, NARC2A, NARC 16B, NARC 1C, NARC 1A, NARC 25, 86604 and 32222 nucleic acid molecules and proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, nonhuman transgenic animals in which a said genes have been introduced or disrupted, fusion proteins, antigenic peptides and antibodies to said proteins. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.